颈动脉血运重建治疗CEA后再狭窄的结局
本研究基于血管质量倡议数据库,回顾性分析2016年9月至2020年4月因同侧CEA后再狭窄接受TCAR、redo-CEA或TFCAS的4425例患者。结果显示,与redo-CEA相比,TCAR与更低的院内卒中/死亡、卒中、心肌梗死、卒中/TIA及卒中/死亡/心肌梗死几率相关;与TFCAS相比,TCAR仅与更低的卒中/TIA几率相关。
要点
- TCAR与redo-CEA相比,院内卒中/死亡、卒中、心梗及复合终点几率更低。
- TCAR与TFCAS相比,仅卒中/TIA几率显著更低,其余终点无差异。
- TCAR与redo-CEA的死亡几率无显著差异。
核心结论
- TCAR治疗CEA后再狭窄的院内卒中、心梗及复合终点几率低于redo-CEA,卒中/TIA几率低于TFCAS。
研究设计与样本
- 回顾性分析血管质量倡议数据库中2016年9月至2020年4月因同侧CEA后再狭窄接受TCAR、redo-CEA或TFCAS的患者,排除既往同侧CAS者,共4425例。
主要发现
- redo-CEA组963例(21.8%),TFCAS组1786例(40.4%),TCAR组1676例(37.9%)。
- TCAR vs redo-CEA:院内卒中/死亡OR 0.41(95%CI 0.24–0.70,P=0.021),卒中OR 0.46(95%CI 0.23–0.93,P=0.03),心梗OR 0.32(95%CI 0.14–0.73,P=0.007),卒中/TIA OR 0.42(95%CI 0.24–0.74,P=0.002),卒中/死亡/心梗OR 0.41(95%CI 0.24–0.70,P=0.001),死亡OR 0.99(95%CI 0.28–3.5,P=0.995)。
- TCAR vs TFCAS:卒中/TIA OR 0.37(95%CI 0.18–0.74,P=0.005),其余终点无显著差异。
临床怎么用
- 对于CEA后再狭窄患者,TCAR或可降低院内卒中、心梗及复合终点风险,但需结合长期证据。
局限性
- 回顾性数据库分析,仅评估院内结局,缺乏长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Restenosis after carotid endarterectomy (CEA) is associated with an increased risk of ipsilateral stroke. The optimal procedural modality for this indication has yet to be determined. Here, we evaluate the in-hospital outcomes of transcarotid artery revascularization (TCAR), redo-CEA, and transfemoral carotid artery stenting (TFCAS) in a large contemporary cohort of patients who underwent treatment for restenosis after CEA. METHODS: We performed a retrospective analysis of all patients in the vascular quality initiative database who underwent TCAR, redo-CEA, or TFCAS after ipsilateral CEA between September 2016 and April 2020. Patients with prior ipsilateral CAS were excluded from this analysis. In-hospital outcomes following TCAR versus CEA and TCAR versus TFCAS were evaluated using multivariate logistic regression analysis. RESULTS: A total of 4425 patients were available for this analysis. There were 963 (21.8%) redo-CEA, 1786 (40.4%) TFCAS, and 1676 (37.9%) TCAR. TCAR was associated with lower odds of in-hospital stroke/death (odds ratio [OR], 0.41 [95% CI, 0.24–0.70], P=0.021), stroke (OR, 0.46 [95% CI, 0.23–0.93], P=0.03), myocardial infarction (MI; OR, 0.32 [95% CI, 0.14–0.73], P=0.007), stroke/transient ischemic attack (OR, 0.42 [95% CI, 0.24–0.74], P=0.002), and stroke/death/MI (OR, 0.41 [95% CI, 0.24–0.70], P=0.001) when compared with redo-CEA. There was no significant difference in the odds of death between the 2 groups (OR, 0.99 [95% CI, 0.28–3.5], P=0.995). TCAR was also associated with lower odds of stroke/transient ischemic attack (OR, 0.37 [95% CI, 0.18–0.74], P=0.005) when compared with TFCAS. There was no significant difference in the odds of stroke, death, MI, stroke/death, or stroke/death/MI between TCAR and TFCAS. CONCLUSIONS: TCAR was associated with significantly lower odds of in-hospital stroke, MI, stroke/transient ischemic attack, stroke/death, and stroke/death/MI when compared with redo-CEA and lower odds of in-hospital stroke/transient ischemic attack when compared with TFCAS. Additional long-term studies are warranted to establish the role of TCAR for the treatment of restenosis after CEA.
引用
- Elsayed N, Ramakrishnan G, Naazie I, et al. Outcomes of Carotid Revascularization in the Treatment of Restenosis After Prior Carotid Endarterectomy. Stroke. 2021. PMID: 34281373. doi:10.1161/STROKEAHA.120.033667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。